407 related articles for article (PubMed ID: 31480348)
1. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
[TBL] [Abstract][Full Text] [Related]
2. Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Yang Y; Lin H; Zhao L; Song Y; Gao Q
Immunotherapy; 2017 Jun; 9(8):629-635. PubMed ID: 28653574
[TBL] [Abstract][Full Text] [Related]
3. [Radiological monitoring of immunotherapy in renal cell carcinoma].
Lennartz S; Persigehl T
Aktuelle Urol; 2021 Sep; 52(5):474-480. PubMed ID: 34428827
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
[TBL] [Abstract][Full Text] [Related]
7. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
8. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
Weinstock M; McDermott DF
Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
10. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
13. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
14. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
Shablak A; Hawkins RE; Rothwell DG; Elkord E
Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
16. Current Immunotherapies for Renal Cell Carcinoma.
Al-Marrawi MY; Holder SL
Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature.
Wu M; Liu J; Seery S; Meng X; Yue J
Front Immunol; 2021; 12():646085. PubMed ID: 34211459
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
19. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
20. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
